Drug Trial Radar · NCT04292080
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Feb 7, 2022
Primary completion
Apr 7, 2027
Study completion Apr 7, 2029
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Conditions
- Age-related Macular Degeneration (AMD)
Interventions
Dimethyl Fumarate (TECFIDERA™)Drug
Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
No active : no treatmentOther
Patients will receive no specific treatment (standard of care) up to 24 months following randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Month 12 in total area of GA Lesion(s) in the study eye (in mm2) as Measured by Fundus Autofluorescence (FAF)Time frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre intercommunal de Créteil
Créteil, Val De Marne, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.